Literature DB >> 20822453

Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses.

Muriel van den Hende1, Anke Redeker, Kitty M C Kwappenberg, Kees L M C Franken, Jan W Drijfhout, Jaap Oostendorp, A Rob P M Valentijn, Loraine M Fathers, Marij J P Welters, Cornelis J M Melief, Gemma G Kenter, Sjoerd H van der Burg, Rienk Offringa.   

Abstract

CD4(+) T cell responses against the E6 oncoprotein of human papillomavirus (HPV) type 16 and 5 closely related members of clade A9 (HPV31, 33, 35, 52, and 58) were charted in peripheral blood mononuclear cell cultures from healthy subjects and patients who underwent HPV16 E6/E7-specific vaccination. Initial analyses with overlapping peptide arrays showed that approximately one-half of the responding subjects displayed reactivity against corresponding E6 peptides from >or=2 HPV types. This suggested immunological cross-reactivity and complicated retrospective evaluation of the infection history of the healthy subjects. Importantly, further dissection of the response by means of enriched and clonal T cell cultures (with protein antigen instead of peptides) revealed that CD4(+) T cells that are capable of efficiently reacting against E6 antigen from multiple HPV types are rare and only occur when epitope sequences are highly conserved. Our data indicate that natural and vaccine-induced HPV16 E6-specific CD4(+) T cell responses are unlikely to mediate efficient cross-protection against other clade A9 members.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20822453     DOI: 10.1086/656367

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Authors:  Qinghua Feng; Huafeng Wei; Janice Morihara; Joshua Stern; Mujun Yu; Nancy Kiviat; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Gynecol Oncol       Date:  2012-07-22       Impact factor: 5.482

Review 2.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

3.  Accuracy of optical spectroscopy for the detection of cervical intraepithelial neoplasia without colposcopic tissue information; a step toward automation for low resource settings.

Authors:  Jose-Miguel Yamal; Getie A Zewdie; Dennis D Cox; E Neely Atkinson; Scott B Cantor; Calum MacAulay; Kalatu Davies; Isaac Adewole; Timon P H Buys; Michele Follen
Journal:  J Biomed Opt       Date:  2012-04       Impact factor: 3.170

4.  A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.

Authors:  William W Greenfield; Shawna L Stratton; Rebecca S Myrick; Rita Vaughn; Lisa M Donnalley; Hannah N Coleman; Maria Mercado; Andrea M Moerman-Herzog; Horace J Spencer; Nancy R Andrews-Collins; Wilbur C Hitt; Gordon M Low; Nirvana A Manning; Samantha S McKelvey; Dora Smith; Michael V Smith; Amy M Phillips; C Matthew Quick; Susanne K Jeffus; Laura F Hutchins; Mayumi Nakagawa
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

5.  The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization.

Authors:  H-M Koskimaa; A Paaso; M J P Welters; S Grénman; K Syrjänen; S H van der Burg; S Syrjänen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-21       Impact factor: 3.267

Review 6.  Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.

Authors:  Elena Muraro; Anna Merlo; Debora Martorelli; Michela Cangemi; Silvia Dalla Santa; Riccardo Dolcetti; Antonio Rosato
Journal:  Front Immunol       Date:  2017-02-27       Impact factor: 7.561

7.  Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.

Authors:  Hanna-Mari Koskimaa; Anna E Paaso; Marij J P Welters; Seija E Grénman; Kari J Syrjänen; Sjoerd H van der Burg; Stina M Syrjänen
Journal:  J Transl Med       Date:  2014-02-13       Impact factor: 5.531

8.  Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative.

Authors:  Hanna-Mari Koskimaa; Anna Paaso; Marij J P Welters; Seija Grénman; Kari Syrjänen; Sjoerd H van der Burg; Stina Syrjänen
Journal:  J Transl Med       Date:  2015-11-25       Impact factor: 5.531

9.  Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design.

Authors:  Sarah R Helman; Sanja Stevanovic; Tracy E Campbell; Mei Li M Kwong; Stacey L Doran; William C Faquin; Christian S Hinrichs
Journal:  JAMA Netw Open       Date:  2018-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.